NEW YORK (GenomeWeb News) – Quest Diagnostics has entered into an agreement with Goldman Sachs to repurchase about $450 million of its stock, the company said in a document filed with the US Securities and Exchange Commission today.

Quest received an initial 7,242,489 shares of its stock on Monday. The number of shares it will buy back under the accelerated share repurchase agreement will be based on the average of the daily volume-weighted average price per share of its stock during the repurchase period.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Researchers find that a personalized medicine approach could help people who experience pain while taking statins, New Scientist reports.

US National Science Foundation is continuing its responsible research conduct training policy despite its flaws, ScienceInsider reports.

A CRISPR-themed meeting explored how the tool could and should be used, Wired reports.

In Science this week: database of proteins' effects on cancer, targeted error correction sequencing, and more.